WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "b0ffe938-a6c4-47ff-b38c-f2add6cc1c97"}, "_deposit": {"created_by": 39, "id": "12214", "owners": [39], "pid": {"revision_id": 0, "type": "depid", "value": "12214"}, "status": "published"}, "_oai": {"id": "oai:redcross.repo.nii.ac.jp:00012214", "sets": ["420"]}, "author_link": ["44350", "27650", "908", "27646", "26914", "7289", "34075", "12080", "910", "34079", "27651", "44361"], "item_10002_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-03-01", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "45", "bibliographicPageStart": "43", "bibliographicVolumeNumber": "40", "bibliographic_titles": [{"bibliographic_title": "高山赤十字病院紀要"}, {"bibliographic_title": "Japanese Red Cross Takayama Hospital", "bibliographic_titleLang": "en"}]}]}, "item_10002_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A lot of studies of O6-methyguanine DNA methyltransferase (MGMT) protein expression have\nbeen reported in glioma. However, there are few reports assessed the protein expression in other\nbrain tumors except glioma.\nMETHODS: Five brain tumors except glioma (two primary central nervous system lymphomas;\nPCNSLs, one germinoma, one hemangioblastoma, and one Rathke’s cleft cyst) were immunostained\nusing a commercial anti-MGMT antibody (Chemicon international:MAB16200;clone MT3.1). Three\nglioblastomas were also immunostained with the same antibody. We assessed MGMT protein\nexpression semiquantitatively (low expression was defined as 20~50% immunostained tumor cells,\nand high expression was defined as >50% immunostained tumor cells ).\nRESULTS: Two PCNSLs were assessed as high expression. Germinoma was also assessed as high\nexpression. In contrast, Hemangioblastoma was assessed as low expression and Rathke’s cleft\ncyst was no expression.\nCONCLUSIONS: By using immunohistochemical assessment of MGMT protein expression, it might\nhelp us to understand the features in brain tumors except glioma.", "subitem_description_type": "Abstract"}]}, "item_10002_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "34079", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "NISHIWAKI, Takayuki"}]}, {"nameIdentifiers": [{"nameIdentifier": "12080", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "TAKENAKA, Katsunobu"}]}, {"nameIdentifiers": [{"nameIdentifier": "27650", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "KATO, Masayasu"}]}, {"nameIdentifiers": [{"nameIdentifier": "27651", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "NONAKA, Yuko"}]}, {"nameIdentifiers": [{"nameIdentifier": "44361", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "CHO, Shinshin"}]}, {"nameIdentifiers": [{"nameIdentifier": "26914", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "OKAMOTO, Kiyohisa"}]}]}, "item_10002_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "高山赤十字病院"}]}, "item_10002_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0387-7027", "subitem_source_identifier_type": "ISSN"}]}, "item_10002_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "西脇, 崇裕貴"}], "nameIdentifiers": [{"nameIdentifier": "34075", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "竹中, 勝信"}], "nameIdentifiers": [{"nameIdentifier": "908", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "加藤, 雅康"}], "nameIdentifiers": [{"nameIdentifier": "910", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "野中, 裕康"}], "nameIdentifiers": [{"nameIdentifier": "27646", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "趙, 振新"}], "nameIdentifiers": [{"nameIdentifier": "44350", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "岡本, 清尚"}], "nameIdentifiers": [{"nameIdentifier": "7289", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "9000001425835", "nameIdentifierScheme": "CiNii ID", "nameIdentifierURI": "http://ci.nii.ac.jp/nrid/9000001425835"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-08-14"}], "displaytype": "simple", "download_preview_message": "", "file_order": 0, "filename": "10西脇崇裕貴.pdf", "filesize": [{"value": "41.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 41200000.0, "url": {"label": "takayama40_010", "url": "https://redcross.repo.nii.ac.jp/record/12214/files/10西脇崇裕貴.pdf"}, "version_id": "0d6e3591-ca46-46dc-b47d-43fd309e4f00"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "MGMT", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lymphoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immunostaining", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MGMT", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lymphoma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immunostaining", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "悪性神経膠芽腫(グリオーマ)以外の脳腫瘍における O6-methylguanine-DNA methyltransferase (MGMT)抗体の染色性の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "悪性神経膠芽腫(グリオーマ)以外の脳腫瘍における O6-methylguanine-DNA methyltransferase (MGMT)抗体の染色性の検討"}, {"subitem_title": "Immunohistochemical study of O6-methyguanine DNA methyltransferase in brain tumors except glioma", "subitem_title_language": "en"}]}, "item_type_id": "10002", "owner": "39", "path": ["420"], "permalink_uri": "https://redcross.repo.nii.ac.jp/records/12214", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-08-14"}, "publish_date": "2017-08-14", "publish_status": "0", "recid": "12214", "relation": {}, "relation_version_is_last": true, "title": ["悪性神経膠芽腫(グリオーマ)以外の脳腫瘍における O6-methylguanine-DNA methyltransferase (MGMT)抗体の染色性の検討"], "weko_shared_id": -1}
悪性神経膠芽腫(グリオーマ)以外の脳腫瘍における O6-methylguanine-DNA methyltransferase (MGMT)抗体の染色性の検討
https://redcross.repo.nii.ac.jp/records/12214
https://redcross.repo.nii.ac.jp/records/122149929d9aa-0001-483e-a6e1-1834f146c80d
名前 / ファイル | ライセンス | アクション |
---|---|---|
takayama40_010 (41.2 MB)
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-08-14 | |||||
タイトル | ||||||
タイトル | 悪性神経膠芽腫(グリオーマ)以外の脳腫瘍における O6-methylguanine-DNA methyltransferase (MGMT)抗体の染色性の検討 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Immunohistochemical study of O6-methyguanine DNA methyltransferase in brain tumors except glioma | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MGMT | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lymphoma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | immunostaining | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | MGMT | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | lymphoma | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | immunostaining | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
西脇, 崇裕貴
× 西脇, 崇裕貴× 竹中, 勝信× 加藤, 雅康× 野中, 裕康× 趙, 振新× 岡本, 清尚 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | A lot of studies of O6-methyguanine DNA methyltransferase (MGMT) protein expression have been reported in glioma. However, there are few reports assessed the protein expression in other brain tumors except glioma. METHODS: Five brain tumors except glioma (two primary central nervous system lymphomas; PCNSLs, one germinoma, one hemangioblastoma, and one Rathke’s cleft cyst) were immunostained using a commercial anti-MGMT antibody (Chemicon international:MAB16200;clone MT3.1). Three glioblastomas were also immunostained with the same antibody. We assessed MGMT protein expression semiquantitatively (low expression was defined as 20~50% immunostained tumor cells, and high expression was defined as >50% immunostained tumor cells ). RESULTS: Two PCNSLs were assessed as high expression. Germinoma was also assessed as high expression. In contrast, Hemangioblastoma was assessed as low expression and Rathke’s cleft cyst was no expression. CONCLUSIONS: By using immunohistochemical assessment of MGMT protein expression, it might help us to understand the features in brain tumors except glioma. |
|||||
書誌情報 |
高山赤十字病院紀要 en : Japanese Red Cross Takayama Hospital 巻 40, p. 43-45, 発行日 2017-03-01 |
|||||
出版者 | ||||||
出版者 | 高山赤十字病院 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0387-7027 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |